Ginkgo Bioworks, a company that designs organisms that can treat liver disorders or recreate the scent of an extinct Hawaiian hibiscus, is considering going public through a merger with a SPAC backed by Harry Sloan, Bloomberg reports, citing people with knowledge of the matter.
Boston-based Ginkgo is exploring a potential combination with Soaring Eagle Acquisition, said the people. A transaction could be valued at more than $20 billion.
Any deal would rank among the biggest SPAC mergers to date. In 2019 when it last raised funding, Ginkgo was ascribed a valuation of $4 billion, Bloomberg News has reported. Read more.
